Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

• Status: Recruiting
• Trial end date: 2023-12-30

Summary

This study is designed to determine the feasibility, safety, tolerability and maximum tolerated dose of Venetoclax in combination with Blinatumomab and to evaluate the response in patients treated with the combination of Venetoclax and Blinatumomab in in patients with hematological relapse or molecular relapse.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Goethe University
• Collaborator: University Hospital Schleswig-Holstein
• Treatments: Blinatumomab; Venetoclax